Teva Pharm faces U.S. patent worries, dip in profits

JERUSALEM (Reuters) - Teva Pharmaceutical Industries profits fell in the second quarter, hurt by a decline in U.S. and European generic drug sales, and its near-term outlook looks bleak in the face of prospective competition for multiple sclerosis drug Copaxone.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news